Literature DB >> 22100020

Reconstruction after esophagectomy for esophageal cancer: retrosternal or posterior mediastinal route?

Mei-Lin Chan1, Chih-Cheng Hsieh, Cheng-Wien Wang, Min-Hsiung Huang, Wen-Hu Hsu, Han-Shui Hsu.   

Abstract

BACKGROUND: The aim of this study is to investigate which reconstructive route is most appropriate for patients undergoing an esophagectomy for esophageal cancer.
METHODS: Clinical data on 110 patients were retrospectively collected by reviewing their medical charts. In order to evaluate the effects of adjuvant radiotherapy, patients were interviewed about the adverse side effects they experienced during and after treatment.
RESULTS: The leakage rate was significantly lower in group that received posterior mediastinal reconstruction compared with the group that received retrosternal reconstruction (7.1% vs. 39%, p = 0.01). There were no significant differences between groups in terms of side effects related to adjuvant chemoradiotherapy or radiotherapy. The quality-of-life reports of patients who received adjuvant radiotherapy were not significantly different between the two study groups.
CONCLUSION: For patients with esophageal cancer who undergo an esophagectomy followed by gastric conduit reconstruction, the posterior mediastinal route is superior to the retrosternal route in regard to anastomotic leakage and hospital mortality. Adjuvant radiotherapy did not influence the postoperative functions of the gastric conduit used for reconstruction in either route.
Copyright © 2011. Published by Elsevier B.V.

Entities:  

Mesh:

Year:  2011        PMID: 22100020     DOI: 10.1016/j.jcma.2011.09.006

Source DB:  PubMed          Journal:  J Chin Med Assoc        ISSN: 1726-4901            Impact factor:   2.743


  7 in total

1.  A non-randomized retrospective observational study on the subcutaneous esophageal reconstruction after esophagectomy: is it feasible in high-risk patients?

Authors:  Jae Ho Chung; Sung Ho Lee; Eunjue Yi; Jae Seung Jung; Jung Wook Han; Tae Sik Kim; Ho Sung Son; Kwang Taik Kim
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

2.  Association of level of anastomosis and anastomotic leak after esophagectomy in anterior mediastinal reconstruction.

Authors:  Katsunori Nishikawa; Tetsuji Fujita; Yako Hasegawa; Yujiro Tanaka; Akira Matsumoto; Norio Mitsumori; Katsuhiko Yanaga
Journal:  Esophagus       Date:  2018-05-31       Impact factor: 4.230

3.  Substernal reconstruction following esophagectomy: operation of last resort?

Authors:  Jacob R Moremen; DuyKhanh P Ceppa; Karen M Rieger; Thomas J Birdas
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

4.  LYMPHOPARIETAL INDEX IN ESOPHAGEAL CANCER IS STRONGER THAN TNM STAGING IN LONG-TERM SURVIVAL PROGNOSIS IN A LATIN-AMERICAN COUNTRY.

Authors:  Manuel Figueroa-Giralt; Catalina Valenzuela; Andrés Torrealba; Attila Csendes; Italo Braghetto; Enrique Lanzarini; Maher Musleh; Owen Korn; Hector Valladares; Solange CortÉs
Journal:  Arq Bras Cir Dig       Date:  2021-01-15

5.  Impact of Reconstruction Route on Postoperative Morbidity After Esophagectomy: Analysis of Esophagectomies in the Japanese National Clinical Database.

Authors:  Hirotoshi Kikuchi; Hideki Endo; Hiroyuki Yamamoto; Soji Ozawa; Hiroaki Miyata; Yoshihiro Kakeji; Hisahiro Matsubara; Yuichiro Doki; Yuko Kitagawa; Hiroya Takeuchi
Journal:  Ann Gastroenterol Surg       Date:  2021-09-06

6.  Dislocation of the gastric conduit reconstructed via the posterior mediastinal route is a significant risk factor for anastomotic disorder after McKeown esophagectomy.

Authors:  Masanobu Nakajima; Hiroto Muroi; Maiko Kikuchi; Junki Fujita; Keisuke Ihara; Masatoshi Nakagawa; Shinji Morita; Takatoshi Nakamura; Satoru Yamaguchi; Kazuyuki Kojima
Journal:  Ann Gastroenterol Surg       Date:  2021-08-12

Review 7.  Esophageal cancer with a double aortic arch: a case report and literature review.

Authors:  Kai Kang; Sheng Wang; Fei Xiong; Jindan Kai; Jianjian Wang; Binfeng Li
Journal:  J Cardiothorac Surg       Date:  2022-03-11       Impact factor: 1.637

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.